

AMENDMENT OF THE CLAIMS

Please amend the claims by canceling pending claims 56-74 (without prejudice) and adding new claims 75-84.

In accordance with 37 C.F.R. § 1.121(c), the following is "a complete listing of all claims ever presented, including the text of all pending and withdrawn claims," and the listing shows their status.

1-74. (cancelled)

75. (new) An immunological assay for the detection and/or quantification of an analyte of human MDA-modified LDL (malondialdehyde-modified low density lipoprotein) and human OxLDL (oxidized low density lipoprotein) in a sample derived from the blood or tissue of a human being, said assay comprising:

(a) contacting the analyte with (i) monoclonal antibody mAb-4E6 produced by hybridoma Hyb4E6, which was deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) under deposit accession number LMBP 1660 CB on April 24, 1997, and (ii) optionally monoclonal antibody mAb-8A2 produced by hybridoma Hyb8A2, which was deposited at the BCCM under deposit accession number LMBP 1661 CB on April 24, 1997; and

(b) thereafter visualizing and/or quantifying a binding reaction between the one or two antibodies and the analyte present in the sample;

wherein the MDA-modified LDL and OxLDL contain at least 60 substituted lysine moieties per apo B-100 (apolipoprotein B-100) moiety.

76. (new) The assay of claim 75 in which the MDA-modified LDL and OxLDL contain at least about 90 substituted lysine moieties per apo B-100 moiety.

77. (new) The assay of claim 75 in which the MDA-modified LDL and OxLDL contain at least about 120 substituted lysine moieties per apo B-100 moiety.

78. (new) The assay of claim 75 in which the MDA-modified LDL and OxLDL contain at least about 210 substituted lysine moieties per apo B-100 moiety.

79. (new) The assay of claim 75 in which the MDA-modified LDL and OxLDL contain at least about 240 substituted lysine moieties per apo B-100 moiety.
80. (new) The assay of claim 75 which is a competitive assay and in which the analyte is contacted with monoclonal antibody mAb-4E6.
81. (new) The competitive assay of claim 80 in which the analyte and monoclonal antibody mAb-4E6 are contacted with a substrate.
82. (new) The assay of claim 75 which is a sandwich assay and in which the analyte is contacted with monoclonal antibody mAb-4E6.
83. (new) The assay of claim 75 in which the analyte is contacted with monoclonal antibodies mAb-4E6 and mAb-8A2.
84. (new) The assay of claim 75 in which the sample is a plasma or serum sample.